EXHIBIT 10.12
VPP SECURITIES PURCHASE
AGREEMENT
This Securities Purchase Agreement (this “
Agreement ”) is dated as of July 31, 2009 between
Capital Growth Systems, Inc., a Florida corporation (the “
Company ”), and each purchaser identified on the
signature pages hereto (each, including its successors and assigns,
a “ Purchaser ” and collectively, the “
Purchasers ”).
WHEREAS, subject to the terms and conditions set
forth in this Agreement and pursuant to Section 4(2) of the
Securities Act of 1933, as amended (the “ Securities
Act ”), and Rule 506 promulgated thereunder, the Company
desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this
Agreement.
NOW, THEREFORE, IN CONSIDERATION of the mutual
covenants contained in this Agreement, and for other good and
valuable consideration, the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as
follows:
ARTICLE I.
DEFINITIONS
1.1
Definitions . In addition to the terms defined
elsewhere in this Agreement: (a) capitalized terms that are not
otherwise defined herein have the meanings given to such terms in
the Debentures (as defined herein), and (b) the following terms
have the meanings set forth in this Section 1.1:
“ Acquiring Person ” shall
have the meaning ascribed to such term in Section 4.7.
“ Action ” shall have the
meaning ascribed to such term in Section 3.1(j).
“ Affiliate ” means any
Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed
under Rule 405 under the Securities Act.
“ Authorized Share Approval ”
means (i) the vote by the stockholders of the Company to approve an
amendment to the Company’s articles or certificate of
incorporation that increases the number of authorized shares of
Common Stock to at least 990,000,000 shares of Common Stock (the
“ Amendment ”) and (ii) the filing by the
Company of the Amendment with the Secretary of State of the State
of Florida and the acceptance of the Amendment by the Secretary of
State of the State of Florida.
“ Board of Directors ” means
the board of directors of the Company.
“ Business Day ” means any
day except Saturday, Sunday, any day which is a federal legal
holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by
law or other governmental action to close.
“ Closing ” means the closing
of the purchase and sale of the Securities pursuant to Section
2.1.
“ Closing Date ” means the
Trading Day when all of the Transaction Documents have been
executed and delivered by the applicable parties thereto, and all
conditions precedent to (i) the Purchasers’ obligations to
pay the Subscription Amount and (ii) the Company’s
obligations to deliver the Securities have been satisfied or
waived.
“ Closing Statement ” means
the Closing Statement in the form Annex A attached
hereto.
“ Collateral Agent ” shall
mean the collateral agent for the benefit of the Debenture holders,
as named in the Security Agreement.
“ Commission ” means the
United States Securities and Exchange Commission.
“ Common Stock ” means the
common stock of the Company, par value $0.001 per share, and any
other class of securities into which such securities may hereafter
be reclassified or changed into.
“ Common Stock Equivalents ”
means any securities of the Company or the Subsidiaries which would
entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, rights,
options, warrants or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive Common Stock.
“ Conversion Price ” shall
have the meaning ascribed to such term in the
Debentures.
“ Consent, Waiver and Amendment
Agreement ” shall have the meaning set forth in Section
2.2 (b)(i) hereof.
“ Debentures ” means the
Original Issue Discount Secured Convertible Debentures due, subject
to the terms therein, due November 30, 2011, issued by the Company
to the Purchasers hereunder, in the form of Exhibit A
attached hereto.
“ Disclosure Schedules ”
shall have the meaning ascribed to such term in Section
3.1.
“ Discussion Time ” shall
have the meaning ascribed to such term in Section
3.2(f).
“ Effective Date ” means the
earlier of (a) the effective date of a Registration Statement and
(b) the date that all of Underlying Shares issuable pursuant to the
Transaction Documents may be sold or are eligible for sale under
Rule 144, without volume or manner-of-sale
restrictions. In determining eligibility for sale under
Rule 144, with respect to the Warrants, it is assumed that the
Warrants shall be exercised pursuant to cashless exercise, so that
the holding period for the Underlying Shares underlying the
Warrants shall tack back to the holding period of the
Warrants.
“ Evaluation Date ” shall
have the meaning ascribed to such term in Section
3.1(r).
“ Exchange Act ” means the
Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.
“ Exempt Issuance ” means the
issuance of (a) shares of Common Stock or options to employees,
officers or directors of the Company pursuant to any stock or
option plan duly adopted for such purpose by a majority of the
non-employee members of the Board of Directors or a majority of the
members of a committee of non-employee directors established for
such purpose, (b) securities upon the exercise or exchange of or
conversion of any Securities issued pursuant to the July Purchase
Agreement or under the March Purchase Agreement (including but not
limited to the Original Issue Discount Debentures expiring November
20, 2015 issued in exchange for the original debentures issued
pursuant to that agreement), the November Purchase Agreement or
this Purchase Agreement (including but not limited to the issuance
of Common Stock: (i) pursuant to Section 2.1 or Section 4.14 of the
July Purchase Agreement; (ii) with respect to the redemption of the
Debentures and the debentures issued pursuant to the March Purchase
Agreement, the November Purchase Agreement or this Purchase
Agreement, or (iii) pursuant to payment of any liquidated damages
with respect to the July Debentures, the July Warrants and the July
Purchase Agreement and the debentures and warrants issued or
issuable pursuant to the March Purchase Agreement,
November Purchase Agreement and this Purchase Agreement) and/or
other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of
this Agreement, (c) securities issued pursuant to acquisitions or
strategic transactions approved by a majority of the disinterested
directors of the Company, provided that any such issuance shall
only be to a Person which is, itself or through its subsidiaries,
an operating company in a business synergistic with the business of
the Company and in which the Company receives benefits in addition
to the investment of funds, but shall not include a transaction in
which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is
investing in securities, (d) for purposes of Section 4.12 only, an
issuance of Common Stock or Common Stock Equivalents, without
registration rights, for cash consideration, to the global carrier
referenced in the Company’s press release dated February 20,
2008, provided, however, any such issuance of Common Stock
Equivalents shall be expressly subordinate to the Debentures
pursuant to a written subordination agreement with the Purchasers
that is acceptable to each Purchaser in its sole and absolute
discretion; (e) outstanding Common Stock and Common Stock
Equivalents as of the date hereof and all securities issuable in
connection with them; and (f) for purposes of Sections 4.12 and
4.13 only, securities (including shares of Commons Stock, warrants
and Common Stock Equivalents) issued in connection with the Senior
Lender Loan Agreement, the terms of which are described in the
Disclosure Schedules hereto).
“ GAAP ” shall have the
meaning ascribed to such term in Section 3.1(h).
“ Holders ” shall mean the
persons or entities holding the Debentures from time to
time.
“ Indebtedness ” shall have
the meaning ascribed to such term in Section 3.1(aa).
“ Intellectual Property Rights
” shall have the meaning ascribed to such term in Section
3.1(o).
“ July Debentures ” shall
mean the up to $10,500,000 in original principal amount (and any
accretions in principal amount thereof pursuant to the terms
thereof) of debentures issued by the Company in July,
2009.
“ July Purchase Agreement ”
shall mean the purchase agreement pursuant to which the July
Debentures and July Warrants are issued.
“ July Purchasers Intercreditor
Agreement ” shall mean the intercreditor agreement in
favor of the Purchasers in the form attached hereto as Exhibit
H.
“ July Warrants ” shall mean
the warrants issued pursuant to the July Purchase
Agreement.
“ Legend Removal Date ” shall
have the meaning ascribed to such term in Section
4.1(c).
“ Liens ” means a lien,
charge, security interest, encumbrance, right of first refusal,
preemptive right or other restriction.
“ March Purchase Agreement ”
means the Securities Purchase Agreement, dated as of March 11,
2008, by and among the Company and each of the purchasers
signatories thereto for the issuance of debentures and
warrants.
“ March Purchasers ”
means the purchasers of the securities issued pursuant to the March
Purchase Agreement and any successors in interest to any of the
debentures and warrants issued pursuant to the March Purchase
Agreement (by way of assignment or cancellation and reissuance of
the same).
“ March Registration Rights
Agreement ” means the Registration Rights Agreement,
dated March 11, 2008, by and among the Company and each of the
March Purchasers.
“ Material Adverse Effect ”
shall have the meaning assigned to such term in Section
3.1(b).
“ Material Permits ” shall
have the meaning ascribed to such term in Section
3.1(m).
“ Maximum Rate ” shall have
the meaning ascribed to such term in Section 5.17.
“ November Purchase Agreement
” means the Securities Purchase Agreement, dated as of
November 19, 2008, by and among the Company and each of the
purchasers signatory thereto for the issuance of debentures and
warrants.
“ November Purchasers ” means
the purchasers of the securities issued pursuant to the November
Purchase Agreement and any successors in interest to any of the
debentures and warrants issued pursuant to the November Purchase
Agreement (by way of assignment or cancellation and reissuance of
the same).
“ November Purchasers Intercreditor
Agreement” means the intercreditor agreement dated as of
November 19, 2008, duly executed by the Company, each of the
Purchasers and each of the November Purchasers and each of the
March Purchasers party thereto.
“ Participation Maximum ”
shall have the meaning ascribed to such term in Section
4.12(a).
“ Person ” means an
individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.
“ Pre-Notice ” shall
have the meaning ascribed to such term in Section
4.12(b).
“ Principal Amount ” means,
as to each Purchaser, the amounts set forth below such
Purchaser’s signature block on the signature pages hereto
next to the heading “Principal Amount,” in United
States Dollars, which shall equal such Purchaser’s
Subscription Amount multiplied by 1.65.
“ Other Debentures
” means the March Debentures, the November Debentures and the
July Debentures.
“ Pro Rata Portion ”
shall have the meaning ascribed to such term in Section
4.12(e).
“ Proceeding ” means an
action, claim, suit, investigation or proceeding (including,
without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or
threatened.
“ Purchaser Party ” shall
have the meaning ascribed to such term in Section 4.10.
“ Registration Statement ”
means a registration statement filed pursuant to Section 4.18,
registering the resale, by the Purchasers, of all of the Underlying
Shares, or any portion thereof.
“ Required Approvals ” shall
have the meaning ascribed to such term in Section
3.1(e).
“ Required Minimum ” means,
as of any date, the maximum aggregate number of shares of Common
Stock then issued or potentially issuable in the future pursuant to
the Transaction Documents, including any Underlying Shares issuable
upon exercise in full of all Warrants or conversion in full of all
Debentures (including Underlying Shares issuable as payment of
interest on the Debentures), ignoring any conversion or exercise
limits set forth therein, and assuming that the Conversion Price is
at all times on and after the date of determination 75% of the then
Conversion Price on the Trading Day immediately prior to the date
of determination.
“ Rule 144 ” means Rule 144
promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially
the same effect as such Rule.
“ SEC Reports ” shall have
the meaning ascribed to such term in Section 3.1(h).
“ Securities ” means the
Debentures, the Warrants, the Warrant Shares and the Underlying
Shares.
“ Securities Act ” means the
Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.
“ Security Agreement ” means
the Security Agreement, dated the date hereof, among the Company
and the Purchasers, in the form of Exhibit E attached
hereto.
“ Security Documents ” shall
mean the Security Agreement, the Subsidiary Guarantees, the
Intercreditor Agreement, and any other documents and filing
required thereunder in order to grant the Purchasers a security
interest in the assets of the Company and the Subsidiaries as
provided in the Security Agreement, including all UCC-1 filing
receipts.
“ Senior Debt ” shall have
the meaning set forth in the July Senior Lender Intercreditor
Agreement.
“ Senior Lender ” shall mean
ACF CGS, L.L.C. as agent for itself and other persons participating
in the Senior Debt.
“ Senior Lender Intercreditor
Agreements ” means: (i) the Intercreditor Agreement,
dated as of November 19, 2008 (“November Senior Lender
Intercreditor Agreement”) among the Senior Lender, the
Company and the holders of the March Debentures and November
Debentures as of such date; (ii) the Intercreditor Agreement among
the Senior Lender, the Company and the Holders of the July
Debentures dated on or about the date of this Agreement
(“July Senior Lender Intercreditor Agreement”); and
(iii) the Intercreditor Agreement among the Senior Lender, the
Company and the holders of the Debentures.
“ Senior Lender Purchasers ”
means the purchasers of the securities issued pursuant to the Loan
and Security Agreement dated as of November 19, 2008 by and among
the Company and its Subsidiaries and ACF CGS, L.L.C. (the “
Senior Lender Loan Agreement ”).
“ Short Sales ” means all
“short sales” as defined in Rule 200 of Regulation SHO
under the Exchange Act (but shall not be deemed to include the
location and/or reservation of borrowable shares of Common
Stock).
“ 67% Majority
” shall mean the Holders of 67% or more aggregate
principal amount of the Debentures issued pursuant to this
Agreement and outstanding from time to time.
“ Subscription Amount ”
means, as to each Purchaser, the aggregate amount to be paid for
Debentures and Warrants purchased hereunder as specified below such
Purchaser’s name on the signature page of this Agreement and
next to the heading “Subscription Amount,” in United
States dollars and in immediately available funds.
“ Subsequent Financing ”
shall have the meaning ascribed to such term in Section
4.12(a).
“ Subsequent Financing Notice
” shall have the meaning ascribed to such term in Section
4.12(b).
“ Subsidiary ” means any
subsidiary of the Company as set forth on Schedule 3.1(a)
and shall, where applicable, include any direct or indirect
subsidiary of the Company formed or acquired after the date
hereof.
“ Subsidiary Guarantee ”
means the Subsidiary Guarantee, dated the date hereof, by each
Subsidiary in favor of the Purchasers, in the form of Exhibit
F attached hereto.
“ Trading Day ” means a day
on which the principal Trading Market is open for
trading.
“ Trading Market ” means the
following markets or exchanges on which the Common Stock is listed
or quoted for trading on the date in question: the American Stock
Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market, the New York Stock Exchange, the OTC
Bulletin Board or the Pink Sheets.
“ Transaction Documents
” means this Agreement, the Debentures, the Warrants, the
Security Agreement, the Subsidiary Guarantee, the Senior Lender
Intercreditor Agreement, the March Purchasers Intercreditor
Agreement, the November Purchasers Intercreditor Agreement, the
Consent, Waiver and Amendment Agreement, all exhibits and schedules
thereto and hereto and any other documents or agreements executed
in connection with the transactions contemplated
hereunder.
“ Transfer Agent ” means
Continental Stock Transfer & Trust Company, the current
transfer agent of the Company with a mailing address of 17 Battery
Place, New York, New York 10004 and a facsimile number of
212-509-5150, and any successor transfer agent of the
Company.
“ Underlying Shares ” means
the shares of Common Stock issued and issuable upon conversion or
redemption of the Debentures and upon exercise of the Warrants and
issued and issuable in lieu of the cash payment of interest on the
Debentures in accordance with the terms of the
Debentures.
“ Variable Rate Transaction ”
shall have the meaning ascribed to such term in Section
4.13(b).
” Vendor Payment Plan”
shall mean the plan put in place by the Company (on
behalf of itself and its subsidiaries) and certain of the trade
creditors of the Company and/or its subsidiaries on or before the
date of this Agreement and as amended from time to time by the
Company with the consent of the Collateral Agent, for the reduction
of past due obligations of the Company and its subsidiaries to such
creditors.
“ VPP Debentures ” shall mean
the Debentures.
“ VPP Warrants ” shall mean
the Warrants.
“ VPP Purchase Agreement ”
shall this Agreement.
“ VWAP ” means, for any date,
the price determined by the first of the following clauses that
applies: (a) if the Common Stock is then listed or quoted on a
Trading Market, the daily volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on the
Trading Market on which the Common Stock is then listed or quoted
as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. New York City time to 4:02 p.m. New York City time); (b)
if the OTC Bulletin Board is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the
nearest preceding date) on the OTC Bulletin Board; (c) if the
Common Stock is not then listed or quoted for trading on the OTC
Bulletin Board and if prices for the Common Stock are then reported
in the “Pink Sheets” published by Pink OTC Markets,
Inc. (or a similar organization or agency succeeding to its
functions of reporting prices), the most recent bid price per share
of the Common Stock so reported; or (d) in all other cases,
the fair market value of a share of Common Stock as determined by
an independent appraiser selected in good faith by the Purchasers
of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company.
“ Warrants ” means,
collectively, the Common Stock purchase warrants delivered to the
Purchasers at the Closing in accordance with Section 2.2(a) hereof,
which Warrants shall be exercisable immediately and have a term of
exercise equal to 5 years from the date of the Authorized Share
Approval, in the form of Exhibit C attached
hereto.
“ Warrant Shares ” means the
shares of Common Stock issuable upon exercise of the
Warrants.
ARTICLE II.
PURCHASE AND SALE
2.1
Closing . On the Closing Date, upon the terms and
subject to the conditions set forth herein, substantially
concurrent with the execution and delivery of this Agreement by the
parties hereto, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase up to $4,125,000, in
the aggregate, in principal amount of the Debentures (representing
an aggregate “Subscription Amount” of up to $2,500,000
and an original issue discount amount of 65% of the cash
Subscription Amount); any Debentures not issued on the Closing Date
may be issued thereafter at such times as are mutually agreeable to
the Company and the Collateral Agent (each such date being a
“Subsequent Closing Date”). Each Purchaser
shall deliver to the Company within one business day following
execution hereof written acknowledgment of reduction in the
obligations owing by the Company or any of its wholly owned
subsidiaries to Purchaser of the Subscription Amount and the
Company shall deliver to each Purchaser its respective Debenture
and a Warrant, as determined pursuant to Section 2.2(a), and the
Company and each Purchaser shall deliver the other items set forth
in Section 2.2 deliverable at the Closing or any Subsequent Closing
Date. Upon satisfaction of the conditions set forth in
Sections 2.2 and 2.3, the Closing shall occur at the offices of
Shefsky & Froelich Ltd. or such other location as the parties
shall mutually agree.
(a) On
the Closing Date, the Company shall deliver or cause to be
delivered to each Purchaser the following:
(i)
this Agreement duly executed by the
Company;
(ii) a
Debenture with a principal amount equal to such Purchaser’s
Subscription Amount multiplied by 1.65, registered in the name of
such Purchaser;
(iii) a
Warrant registered in the name of such Purchaser to purchase up to
a number of shares of Common Stock equal to 75% of such
Purchaser’s Subscription Amount divided by $0.24, with an
exercise price equal to $0.24, subject to adjustment
therein;
(iv) the
Security Agreement, duly executed by the Company and each
Subsidiary, along with all of the Security Documents, including the
Subsidiary Guarantee, duly executed by the parties
thereto;
(v) a
form of consent, waiver and amendment agreement issued by: (A) the
Senior Lender Purchasers in the form attached as Exhibit I-1
(“Senior Lender Consent, Waiver and Amendment
Agreement”); and (B) holders of not less than 67% of the
outstanding principal amount of the March Debentures and the
November Debentures in the form attached as Exhibit I-2
(“Other Debenture Holders’ Consent, Wavier and
Amendment Agreement”), consenting to the transactions
contemplated herein;
(vi) the
July Senior Lender Intercreditor Agreement, duly executed by the
Company and the Senior Lender Purchasers, if required by Senior
Lender ; and
(vii) the
July Purchasers Intercreditor Agreement, duly executed by the
Company and each of the July Purchasers.
(viii) evidence
of the initial closing of the sale of July Debentures.
(b) On
the Closing Date, each Purchaser shall deliver or cause to be
delivered to the Company the following (unless waived by the
Company with the consent of the Collateral Agent):
|
|
|
this
Agreement duly executed by such Purchaser;
|
(ii)
such Purchaser’s proof of funding of the Subscription Amount
by delivery of written acknowledgment on the counterpart signature
page hereof of the corresponding offset in the amount of monies
otherwise owing from the Company or any of its wholly owned
subsidiaries to the Purchaser.
(iii) the
Security Agreement duly executed by such Purchaser;
(iv)
the July Senior Lender Intercreditor Agreement duly executed by
such Purchaser; and
(v)
the July Purchasers Intercreditor Agreement duly executed by such
Purchaser .
(c) .
C losing Conditions.
(a) The
obligations of the Company hereunder in connection with the Closing
are subject to the following conditions being met:
(i)
the accuracy in all material respects on the Closing Date of
the representations and warranties of the Purchasers contained
herein;
(ii)
all obligations, covenants and agreements of each
Purchaser required to be performed at or prior to the Closing Date
shall have been performed; and
(iii) the
delivery by each Purchaser of the items set forth in Section 2.2(b)
of this Agreement.
(b) The
respective obligations of the Purchasers hereunder in connection
with the Closing are subject to the following conditions being met
or waived by the Purchasers.
(i) the
accuracy in all material respects when made and on the Closing Date
of the representations and warranties of the Company contained
herein;
(ii) all
obligations, covenants and agreements of the Company required to be
performed at or prior to the Closing Date shall have been
performed;
(iii) the
delivery of the consent, waiver and amendment agreement, in the
form attached hereto as Exhibit I-1 , duly executed by the
parties named therein;
(iv) there
shall have been no Material Adverse Effect with respect to the
Company since the date hereof;
(v) from
the date hereof to the Closing Date, trading in the Common Stock
shall not have been suspended by the Commission and, at
any time prior to the Closing Date, a banking moratorium shall not
have been declared either by the United States or New York State
authorities nor shall there have occurred any material outbreak or
escalation of hostilities or other national or international
calamity of such magnitude in its effect on, or any material
adverse change in, any financial market which, in each case, in the
reasonable judgment of each Purchaser, makes it impracticable or
inadvisable to purchase the Securities at the Closing;
(vi) subscriptions
for no less than $3,500,000 of July Debenture Subscription Amount
must have been received by the Company, and the holders
of Other Debentures holding not less than 67% of the outstanding
Other Debentures principal amount must have executed the Consent,
Waiver and Amendment Agreement;
(vii) the
Company shall have documented a restructuring plan with the holders
of not less than 60% of outstanding accounts payable of the Company
which are over 60 days outstanding; and
(viii) Senior
Lender and the Company shall have amended the Senior Lender Loan
Agreement with respect to the covenants in a manner
satisfactory to the Company and Aequitas Capital Management, Inc.
(“Aequitas”) and the loan subject to the Senior Lender
Loan Agreement shall continue to have a maturity date no earlier
than its original maturity date, and with the Senior Lender having
waived all know defaults under the Senior Loan Agreement (including
with respect to the forbearance agreement dated as of July 7,
2009—“Forbearance Agreement”).
ARTICLE III.
REPRESENTATIONS AND
WARRANTIES
3.1
Representations and Warranties of the Company
. Except as set forth in the Disclosure Schedules, which
Disclosure Schedules shall be deemed a part hereof and shall
qualify any representation or otherwise made herein to the extent
of the disclosure contained in the corresponding section of the
Disclosure Schedules, the Company hereby makes the following
representations and warranties to each Purchaser:
(a)
Subsidiaries . All of the direct and indirect
subsidiaries of the Company are set forth on Schedule 3.1(a)
. Except as set forth on Schedule 3.1(a) , the
Company owns, directly or indirectly, all of the capital stock or
other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital
stock of each Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities.
(b)
Organization and Qualification . The Company and
each of the Subsidiaries is an entity duly incorporated or
otherwise organized, validly existing and except as noted in
Schedule 3.1(b), in good standing under the laws of the
jurisdiction of its incorporation or organization, with the
requisite power and authority to own and use its properties and
assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in
violation or default of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other
organizational or charter documents. Each of the Company
and the Subsidiaries is duly qualified to conduct business and
except as noted in Schedule 3.1(b) is in good standing as a foreign
corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such
qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, could not have
or reasonably be expected to result in: (i) a material adverse
effect on the legality, validity or enforceability of any
Transaction Document, (ii) a material adverse effect on the results
of operations, assets, business, prospects or condition (financial
or otherwise) of the Company and the Subsidiaries, taken as a
whole, or (iii) a material adverse effect on the Company’s
ability to perform in any material respect on a timely basis its
obligations under any Transaction Document (any of (i), (ii) or
(iii), a “ Material Adverse Effect ”) and no
Proceeding has been instituted in any such jurisdiction revoking,
limiting or curtailing or seeking to revoke, limit or curtail such
power and authority or qualification.
(c)
Authorization; Enforcement . The Company has the
requisite corporate power and authority to enter into and to
consummate the transactions contemplated by each of the Transaction
Documents and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of each of the
Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly
authorized by all necessary action on the part of the Company and
no further action is required by the Company, the Board of
Directors or the Company’s stockholders in connection
therewith other than in connection with the Required
Approvals. Each Transaction Document to which it is a
party has been (or upon delivery will have been) duly executed by
the Company and, when delivered in accordance with the terms hereof
and thereof, will constitute the valid and binding obligation of
the Company enforceable against the Company in accordance with its
terms, except: (i) as limited by general equitable principles and
applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or
other equitable remedies and (iii) insofar as indemnification and
contribution provisions may be limited by applicable
law.
(d)
No Conflicts . Subject to receipt of the Senior
Lender Consent, Waiver and Amendment Agreement and the Other
Debenture Holders’ Consent, Waiver and Amendment Agreement,
the execution, delivery and performance by the Company of the
Transaction Documents to which it is a party and the consummation
by it of the other transactions contemplated hereby and thereby do
not and will not: (i) conflict with or violate any provision of the
Company’s or any Subsidiary’s certificate or articles
of incorporation, bylaws or other organizational or charter
documents, or (ii) conflict with, or constitute a default (or an
event that with notice or lapse of time or both would become a
default) under, result in the creation of any Lien upon any of the
properties or assets of the Company or any Subsidiary, or give to
others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of,
any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or
by which any property or asset of the Company or any Subsidiary is
bound or affected, (iii) subject to the Required Approvals,
conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the
Company or a Subsidiary is subject (including federal and state
securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the
case of each of clauses (ii) and (iii), such as could not have or
reasonably be expected to result in a Material Adverse
Effect.
(e)
Filings, Consents and Approvals . The Company is
not required to obtain any consent, waiver, authorization or order
of, give any notice to, or make any filing or registration with,
any court or other federal, state, local or other governmental
authority or other Person in connection with the execution,
delivery and performance by the Company of the Transaction
Documents, other than: (i) the filings required pursuant to Section
4.6, (ii) the notice and/or application(s) to each applicable
Trading Market for the issuance and sale of the Securities and the
listing of the Underlying Shares for trading thereon in the time
and manner required thereby, and (iii) the filing of Form D with
the Commission and such filings as are required to be made under
applicable state securities laws (collectively, the “
Required Approvals ”).
(f)
Issuance of the Securities
. The Securities (other than the Underlying Shares) are
duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly
issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company other than restrictions on transfer provided
for in the Transaction Documents. Subject only to the
Authorized Share Approval, the Underlying Shares, when issued in
accordance with the terms of the Transaction Documents, will be
validly issued, fully paid and nonassessable, free and clear of all
Liens imposed by the Company other than restrictions on transfer
provided for in the Transaction Documents.
(g)
Capitalization . The capitalization of the
Company is as set forth on Schedule 3.1(g) , which
Schedule 3.1(g) shall also include the number of shares of
Common Stock owned beneficially, and of record, by Affiliates of
the Company as of the date hereof. The Company has not issued any
capital stock since its most recently filed periodic report under
the Exchange Act, other than pursuant to the exercise of employee
stock options under the Company’s stock option plans, the
issuance of shares of Common Stock to employees pursuant to the
Company’s employee stock purchase plans and pursuant to the
conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the
Exchange Act or as reflected on Schedule 3.1(g)
. Except as set forth on Schedule 3.1(g)(i) , no
Person has any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the
transactions contemplated by the Transaction
Documents. Except as a result of the purchase and sale
of the Securities or on Schedule 3.1(g) , there are no
outstanding options, warrants, scrip rights to subscribe to, calls
or commitments of any character whatsoever relating to, or
securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any Person any right to subscribe
for or acquire any shares of Common Stock, or contracts,
commitments, understandings or arrangements by which the Company or
any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents. Except as set forth on
Schedule 3.1(g)(ii) , the issuance and sale of the
Securities will not obligate the Company to issue shares of Common
Stock or other securities to any Person (other than the Purchasers)
and will not result in a right of any holder of Company securities
to adjust the exercise, conversion, exchange or reset price under
any of such securities. All of the outstanding shares of capital
stock of the Company are validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and
state securities laws, and none of such outstanding shares was
issued in violation of any preemptive rights or similar rights to
subscribe for or purchase securities. Except as set
forth on Schedule 3.1(g)(iii) , no further approval or
authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the
Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the
Company’s capital stock to which the Company is a party or,
to the knowledge of the Company, between or among any of the
Company’s stockholders.
(h)
SEC Reports; Financial Statements . Except for
the Form 10-K for the year ended December 31, 2008 and Form 10-Q
for the quarter ended March 31, 2009, which are unfiled as of the
date hereof, the Company has filed all reports, schedules, forms,
statements and other documents required to be filed by the Company
under the Securities Act and the Exchange Act, including pursuant
to Section 13(a) or 15(d) thereof, for the two years preceding the
date hereof (or such shorter period as the Company was required by
law or regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by
reference therein, being collectively referred to herein as the
“ SEC Reports ”) on a timely basis or has
received a valid extension of such time of filing and has filed any
such SEC Reports prior to the expiration of any such
extension. Except as noted on Schedule 3.1(h) ,
or as otherwise disclosed in subsequently filed SEC Reports filed
prior to the date hereof, as of their respective dates, the SEC
Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of
the SEC Reports, when filed except as otherwise disclosed in
subsequently filed SEC Reports filed prior to the date hereof,
contained any untrue statement of a material fact or omitted to
state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the
circumstances under which they were made, not
misleading. Except as described on Schedule
3.1(h) , the Company has never been an issuer subject to Rule
144(i) under the Securities Act. Except as otherwise
disclosed in Schedule 3.1(h) or subsequently filed SEC
Reports filed prior to the date hereof, the financial statements of
the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at
the time of filing. Except as otherwise disclosed in
Schedule 3.1(h) or subsequently filed SEC Reports filed
prior to the date hereof, such financial statements have been
prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis during the
periods involved (“ GAAP ”), except as may be
otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not
contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company and its
consolidated Subsidiaries as of and for the dates thereof and the
results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.
(i)
Material Changes . Other
than as set forth on Schedule 3.1(i) , since the date of the
latest audited financial statements included within the SEC
Reports, except as specifically disclosed in a subsequent SEC
Report filed prior to the date hereof: (i) there has been no event,
occurrence or development that has had or that could reasonably be
expected to result in a Material Adverse Effect, (ii) the Company
has not incurred any liabilities (contingent or otherwise) other
than (A) trade payables and accrued expenses incurred in the
ordinary course of business consistent with past practice or in
connection with the transaction contemplated by this Agreement and
(B) liabilities not required to be reflected in the Company’s
financial statements pursuant to GAAP or disclosed in filings made
with the Commission, (iii) the Company has not altered its method
of accounting, (iv) the Company has not declared or made any
dividend or distribution of cash or other property to its
stockholders or purchased, redeemed or made any agreements to
purchase or redeem any shares of its capital stock and (v) the
Company has not issued any equity securities to any officer,
director or Affiliate, except pursuant to existing Company stock
option plans. The Company does not have pending before the
Commission any request for confidential treatment of
information. Except for the issuance of the Securities
contemplated by this Agreement and the other transactions
contemplated by the Transaction Documents or as set forth on
Schedule 3.1(i) , no event, liability or development has
occurred or exists with respect to the Company or its Subsidiaries
or their respective business, properties, operations or financial
condition, that would be required to be disclosed by the Company
under applicable securities laws at the time this representation is
made or deemed made that has not been publicly disclosed at least 1
Trading Day prior to the date that this representation is
made.
(j)
Litigation . There is no
action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any
of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an
“ Action ”) which (i) adversely affects or
challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) could, if there
were an unfavorable decision, have or reasonably be expected to
result in a Material Adverse Effect, except as noted in Schedule
3.1(j) . Neither the Company nor any Subsidiary, nor
any director or officer thereof, is or has been the subject of any
Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty,
except as set forth on Schedule 3.1(j) . There
has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer
of the Company. The Commission has not issued any stop
order or other order suspending the effectiveness of any
registration statement filed by the Company or any Subsidiary under
the Exchange Act or the Securities Act.
(k)
Labor Relations . No material labor dispute
exists or, to the knowledge of the Company, is imminent with
respect to any of the employees of the Company which could
reasonably be expected to result in a Material Adverse
Effect. None of the Company’s or its
Subsidiaries’ employees is a member of a union that relates
to such employee’s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is
a party to a collective bargaining agreement, and the Company and
its Subsidiaries believe that their relationships with their
employees are good. No executive officer, to the
knowledge of the Company, is, or is now expected to be, in
violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or
non-competition agreement, or any other contract or agreement or
any restrictive covenant in favor of any third party, and the
continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. Except as
disclosed on Schedule 3.1(k) , the Company and its
Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages
and hours, except where the failure to be in compliance could not,
individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.
(l)
Compliance . Except as set forth on
Schedule 3.1(l) , neither the Company nor any Subsidiary:
(i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of
time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received
notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or
any of its properties is bound (whether or not such default or
violation has been waived), (ii) is in violation of any order of
any court, arbitrator or governmental body or (iii) is or has been
in violation of any statute, rule or regulation of any governmental
authority, including without limitation all foreign, federal, state
and local laws applicable to its business and all such laws that
affect the environment, except in each case as could not have or
reasonably be expected to result in a Material Adverse
Effect.
(m)
Regulatory Permits . Except as disclosed on
Schedule 3.1(m) , the Company and the Subsidiaries possess
all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities
necessary to conduct their respective businesses as described in
the SEC Reports, except where the failure to possess such permits
could not reasonably be expected to result in a Material Adverse
Effect (“ Material Permits ”), and neither the
Company nor any Subsidiary has received any notice of proceedings
relating to the revocation or modification of any Material
Permit.
(n)
Title to Assets . Except for the liens set forth
on Schedule 3.1(n) , the Company and the Subsidiaries have
good and marketable title in fee simple to all real property owned
by them and good and marketable title in all personal property
owned by them that is material to the business of the Company and
the Subsidiaries, in each case free and clear of all Liens, except
for Liens as do not materially affect the value of such property
and do not materially interfere with the use made and proposed to
be made of such property by the Company and the Subsidiaries and
Liens for the payment of federal, state or other taxes, the payment
of which is neither delinquent nor subject to
penalties. Any real property and facilities held under
lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with which the Company and
the Subsidiaries are in compliance.
(o)
Patents and Trademarks . The Company and the
Subsidiaries have, or have rights to use, all patents, patent
applications, trademarks, trademark applications, service marks,
trade names, trade secrets, inventions, copyrights, licenses and
other intellectual property rights and similar rights as described
in the SEC Reports as necessary or material for use in connection
with their respective businesses and which the failure to so could
have a Material Adverse Effect (collectively, the “
Intellectual Property Rights ”). Neither
the Company nor any Subsidiary has received a notice (written or
otherwise) that any of the Intellectual Property Rights used by the
Company or any Subsidiary violates or infringes upon the rights of
any Person. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing
infringement by another Person of any of the Intellectual Property
Rights. The Company and its Subsidiaries have taken
reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse
Effect.
(p)
Insurance . The Company and the Subsidiaries are
insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are prudent and
customary in the businesses in which the Company and the
Subsidiaries are engaged, including, but not limited to, directors
and officers insurance coverage in the amount of $10.0
million. Neither the Company nor any Subsidiary has any
reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to
continue its business without a significant increase in
cost.
(q)
Transactions with Affiliates and Employees
. Except as set forth in the SEC Reports, none of the
officers or directors of the Company and, to the knowledge of the
Company, none of the employees of the Company is presently a party
to any transaction with the Company or any Subsidiary (other than
for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or
personal property to or from, or otherwise requiring payments to or
from any officer, director or such employee or, to the knowledge of
the Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director,
trustee or partner, in each case in excess of $120,000 other than
for: (i) payment of salary or consulting fees for services
rendered, (ii) reimbursement for expenses incurred on behalf of the
Company and (iii) other employee benefits, including stock option
agreements under any stock option plan of the Company.
(r)
Sarbanes-Oxley; Internal Accounting
Controls . Except as set forth on Schedule
3.1(r) , the Company is in material compliance with all
provisions of the Sarbanes-Oxley Act of 2002 which are applicable
to it as of the Closing Date. Except as noted on
Schedule 3.1(r), the Company and the Subsidiaries maintain a
system of internal accounting controls sufficient to provide
reasonable assurance that: (i) transactions are executed in
accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP
and to maintain asset accountability, (iii) access to assets is
permitted only in accordance with management’s general or
specific authorization, and (iv) the recorded accountability for
assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences.
Except as noted on Schedule 3.1(r), the Company has
established disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and
designed such disclosure controls and procedures to ensure that
information required to be disclosed by the Company in the reports
it files or submits under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the
Commission’s rules and forms. The Company’s
certifying officers have evaluated the effectiveness of the
Company’s disclosure controls and procedures as of the end of
the period covered by the Company’s most recently filed
periodic report under the Exchange Act (such date, the “
Evaluation Date ”). The Company presented
in its most recently filed periodic report under the Exchange Act
the conclusions of the certifying officers about the effectiveness
of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Except as noted
in Schedule 3.1(r), since the Evaluation Date, there have
been no changes in the Company’s internal control over
financial reporting (as such term is defined in the Exchange Act)
that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial
reporting.
(s)
Certain Fees . No
brokerage or finder’s fees or commissions are or will be
payable by the Company to any broker, financial advisor or
consultant, finder, placement agent, investment banker, bank or
other Person with respect to the transactions contemplated by the
Transaction Documents, except as set forth on Schedule
3.1(s) . The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or
on behalf of other Persons for fees of a type contem